She spent her life lying about who she was. Her daughter found out. It changed everything.

“Promise me,” she pleaded, “you won’t tell anyone until after I die. How will I hold my head up with my friends?”

For two years, I’d waited for the right moment to confront my mother with the shocking discovery I made in 1995, while I was scrolling through the 1900 Louisiana census records.

In the records, my mother’s father and his entire family were designated black. With her pale olive skin and European features, my mother had kept her ethnicity concealed for nearly a lifetime.


The discovery had left me reeling, confused, and in need of answers. My sense of white identity had been shattered. My mother’s visit to my home in Illinois seemed like the right moment to bring it up. This was not a conversation I wanted to have on the phone.

But my mother’s fearful plea for secrecy only added to my confusion about my racial identity.

Reluctantly, I agreed to keep my mother’s secret. For 17 years, I told no one except my husband, my two children, and two close friends that my mother was passing as white. It was the longest and most difficult secret I’d ever held.

Over the course of those 17 years, I tried unsuccessfully to break through my mother’s wall of silence. Her refusal to talk about her mixed race only fueled my curiosity. How had she deceived my racist, white father? Why was she so fearful and ashamed of her black heritage?

The author's mother, Alvera Fredric. Photo via Gail Lukasik.

Using my skills as a mystery author, I started sifting through the details of her life, looking for clues that would help me understand her. But this real-life mystery only intensified as I tried to sort truth from fiction.

My mother had always told me that she didn't visit her family in New Orleans because there were just too many sad memories — now I wondered if she was really just afraid that if we visited we’d meet family members who were not passably white. On several occasions, her mother and her sister visited us in Ohio, but they appeared white and no one hinted otherwise. But my uncle never visited — was it because he was darker than the rest? Was the reason my mother had never shown me photographs of my grandfather growing up because he was visibly black?

Piecing my mother's life together, I marveled at how she endured living in a predominantly white suburb with a racist husband.

My father’s racism was a reflection of his upbringing in a close-knit Cleveland ethnic neighborhood. Though he never used the n-word, he was still vocal about his bigotry, referring to African-Americans using other racial slurs, deriding black people for what he perceived as their lack of ambition and their criminality. He had no idea that he was in fact deriding his wife, my mother.

My mother reprimanded him with little vigor. Was she afraid of bringing too much attention to the race issue? Or had she convinced herself that she deserved it for the lie that sat at the heart of their marriage? In escaping the Jim Crow South, coming North and marrying my father, she must have thought gaining white privilege was worth the price of losing family ties and her authentic self.

The irony was that in gaining white privilege, the onslaught of racism was splayed open to her.

Its ugly face could now be shared with her, a “white” woman. Every day she had to live with the paradox of what W.E.B. Du Bois called “two-ness,” the ambivalence of people of mixed European and African ancestry. If a mixed-race person is white enough to pass, how do they deal with the trappings of a racist culture where you’re forced to choose a side?

As if in self-defense, or maybe retaliation, for my father’s racism, she imbued me with a moral imperative to respect all people regardless of their color. As a child, I listened with rapt attention to the story of the old black woman on Canal Street burdened with packages who didn’t move off the sidewalk for a white man. He shoved her aside like so much trash and called her the n-word. “That wasn’t right,” my mother told me. “But that’s how it was in New Orleans back then.”

Now I understood the clues concealed in that story, that she was hinting at her hidden self or maybe preparing me to accept the part of her she’d left behind in New Orleans.

The author, Gail Lukasik. Photo via Gail Lukasik.

After my mother’s death in 2014, I was freed of my vow.

In what can only be called serendipity, I was presented with an opportunity to solve the uncertainly of my racial heritage on PBS’s Genealogy Roadshow.” I traced the Frederic family back to 18th-century Louisiana. I discovered slave-owners, enslaved women, and free people of color. Through the centuries, I saw how shifting racial laws had affected my family, boxing them into racial categories that hindered them.

Three days after my appearance on the show, my mother’s family found me. My “new” family welcomed me with generosity and love, neither judging my mother nor rejecting me. At a welcome home party in New Orleans, I met my new uncle, two aunts, and slews of cousins. We were every shade of skin from darkest ebony to whitest white and all the shades in between. Suddenly, I was part of a multiracial family.

Although I could check “other” or “multiracial” when asked my race on a form, I still identify as a white woman.

At this late point, it would be disingenuous of me to claim any other identity. I’ve enjoyed white privilege my entire life. I will never forget my mother’s haunted look as she said, “How will I hold my head up with my friends?” I bear no rancor toward her for not telling me of her mixed-race heritage. I feel only sorrow that, even after I knew, she was unable to share with me her feelings about who she really was and the life she had lived.

Even so, I find solace and pride in finally knowing the truth of my own heritage and the mixed-raced family I am a part of.

This story originally appeared on The Lily, a publication of Washington Post, and is reprinted here with permission.

The airline industry was one of the hardest hit by the COVID-19 pandemic, as global and domestic travel came to a screeching halt last spring. When the pandemic was officially declared in March of 2020, no one knew what to expect or how long the timeline of lockdowns and life changes would last.

Two weeks after the declaration, Delta pilot Chris Dennis flew one of the airline's planes to Victorville, CA for storage. He shared photos on Facebook that day of empty planes neatly lined up, saying it was a day he would remember for the rest of his life.

"Chilling, apocalyptic, surreal...all words that still don't fit what is happening in the world," he wrote. "Each one of these aircraft represents hundreds of jobs, if not more."

He added:

Keep Reading Show less

The airline industry was one of the hardest hit by the COVID-19 pandemic, as global and domestic travel came to a screeching halt last spring. When the pandemic was officially declared in March of 2020, no one knew what to expect or how long the timeline of lockdowns and life changes would last.

Two weeks after the declaration, Delta pilot Chris Dennis flew one of the airline's planes to Victorville, CA for storage. He shared photos on Facebook that day of empty planes neatly lined up, saying it was a day he would remember for the rest of his life.

"Chilling, apocalyptic, surreal...all words that still don't fit what is happening in the world," he wrote. "Each one of these aircraft represents hundreds of jobs, if not more."

He added:

Keep Reading Show less
True

Each year, an estimated 1.8 million people in the United States are affected by cancer — most commonly cancers of the breast, lung, prostate, and blood cancers such as leukemia. While not everyone overcomes the disease, thanks to science, more people are surviving — and for longer — than ever before in history.

We asked three people whose lives have been impacted by cancer to share their stories – how their lives were changed by the disease, and how they're using that experience to change the future of cancer treatments with the hope that ultimately, in the fight against cancer, science will win. Here's what they had to say.

Celine Ryan, 55, engineer database programmer and mother of five from Detroit, MI

Photo courtesy of Celine Ryan

In September 2013, Celine Ryan woke up from a colonoscopy to some traumatic news. Her gastroenterologist showed her a picture of the cancerous mass they found during the procedure.

Ryan and her husband, Patrick, had scheduled a colonoscopy after discovering some unusual bleeding, so the suspicion she could have cancer was already there. Neither of them, however, were quite prepared for the results to be positive -- or for the treatment to begin so soon. Just two days after learning the news, Ryan had surgery to remove the tumor, part of her bladder, and 17 cancerous lymph nodes. Chemotherapy and radiation soon followed.

Ryan's treatment was rigorous – but in December 2014, she got the devastating news that the cancer, once confined to her colon, had spread to her lungs. Her prognosis, they said, was likely terminal.

But rather than give up hope, Ryan sought support from online research, fellow cancer patients and survivors, and her medical team. When she brought up immunotherapy to her oncologist, he quickly agreed it was the best course of action. Ryan's cancer, like a majority of colon and pancreatic cancers, had been caused by a defect on the gene KRAS, which can result in a very aggressive cancer that is virtually "undruggable." According to the medical literature, the relatively smooth protein structure of the KRAS gene meant that designing inhibitors to bind to surface grooves and treat the cancer has been historically difficult. Through her support systems, Ryan discovered an experimental immunotherapy trial at the National Institutes of Health (NIH) in Bethesda, MD., and called them immediately to see if she was eligible. After months of trying to determine whether she was a suitable candidate for the experimental treatment, Ryan was finally accepted.

The treatment, known as tumor-infiltrating lymphocyte therapy, or TIL, is a testament to how far modern science has evolved. With this therapy, doctors remove a tumor and harvest special immune cells that are found naturally in the tumor. Doctors then grow the cells in a lab over the next several weeks with a protein that promotes rapid TIL growth – and once the cells number into the billions, they are infused back into the patient's body to fight the cancer. On April 1, 2015, Ryan had her tumor removed at the NIH. Two months later, she went inpatient for four weeks to have the team "wash out" her immune system with chemotherapy and infuse the cells – all 148 billion of them – back into her body.

Six weeks after the infusion, Ryan and Patrick went back for a follow-up appointment – and the news they got was stunning: Not only had no new tumors developed, but the six existing tumors in her lungs had shrunk significantly. Less than a year after her cell infusion, in April 2016, the doctors told Ryan news that would have been impossible just a decade earlier: Thanks to the cell infusion, Ryan was now considered NED – no evaluable disease. Her body was cancer-free.

Ryan is still NED today and continuing annual follow-up appointments at the NIH, experiencing things she never dreamed she'd be able to live to see, such as her children's high school and college graduations. She's also donating her blood and cells to the NIH to help them research other potential cancer treatments. "It was an honor to do so," Ryan said of her experience. "I'm just thrilled, and I hope my experience can help a lot more people."

Patrice Lee, PhD, VP of Pharmacology, Toxicology and Exploratory Development at Pfizer

Photo courtesy of Patrice Lee

Patrice Lee got into scientific research in an unconventional way – through the late ocean explorer Jacques Cousteau.

Lee never met Cousteau but her dreams of working with him one day led her to pursue a career in science. Initially, Lee completed an undergraduate degree in marine biology; eventually, her interests changed and she decided to get a dual doctoral degree in physiology and toxicology at Duke University. She now works at Pfizer's R&D site in Boulder, CO (formerly Array BioPharma), leading a group of scientists who determine the safety and efficacy of new oncology drugs.

"Scientists focused on drug discovery and development in the pharmaceutical industry are deeply committed to inventing new therapies to meet unmet needs," Lee says, describing her field of work. "We're driven to achieve new medicines and vaccines as quickly as possible without sacrificing safety."

Among the drugs Lee has helped develop during her career, including cancer therapies, she says around a dozen are currently in development, while nine have received FDA approval — an incredible accomplishment as many scientists spend their careers without seeing their drug make it to market. Lee's team is particularly interested in therapies for brain metastases — something that Lee says is a largely unmet need in cancer research, and something her team is working on from a variety of angles. "Now that we've had rapid success with mRNA vaccine technology, we hope to explore what the future holds when applying this technology to cancers," Lee says.

But while evaluating potential cancer therapies is a professional passion of Lee's, it's also a mission that's deeply personal. "I'm also a breast cancer survivor," she says. "So I've been on the other side of things and have participated in a clinical trial."

However, seeing how melanoma therapies that she helped develop have affected other real-life cancer patients, she says, has been a highlight of her career. "We had one therapy that was approved for patients with BRAF-mutant metastatic melanoma," Lee recalls. "Our team in Boulder was graced by a visit from a patient that had benefited from these drugs that we developed. It was a very special moment for the entire team."

None of these therapies would be available, Lee says without rigorous science behind it: "Facts come from good science. Facts will drive the development of new drugs, and that's what will help patients."

Chiuying "Cynthia" Kuk (they/them) MS, 34, third-year medical student at Michigan State University College of Human Medicine

Photo courtesy of Cynthia Kuk

Cynthia Kuk was just 10 years old when they had a conversation that would change their life forever.

"My mother, who worked as a translator for the government at the time, had been diagnosed with breast cancer, and after her chemotherapy treatments she would get really sick," Kuk, who uses they/them pronouns, recalls. "When I asked my dad why mom was puking so much, he said it was because of the medicine she was taking that would help her get better."

Kuk's response was immediate: "That's so stupid! Why would a medicine make you feel worse instead of better? When I'm older, I want to create medicine that won't make people sick like that."

Nine years later, Kuk traveled from their native Hong Kong to the United States to do exactly that. Kuk enrolled in a small, liberal arts college for their Bachelor's degree, and then four years later started a PhD program in cancer research. Although Kuk's mother was in remission from her cancer at the time, Kuk's goal was the same as it had been as a 10-year-old watching her suffer through chemotherapy: to design a better cancer treatment, and change the landscape of cancer research forever.

Since then, Kuk's mission has changed slightly.

"My mom's cancer relapsed in 2008, and she ended up passing away about five years after that," Kuk says. "After my mom died, I started having this sense of urgency. Cancer research is such that you work for twenty years, and at the end of it you might have a fancy medication that could help people, but I wanted to help people now." With their mother still at the forefront of their mind, Kuk decided to quit their PhD program and enter medical school.

Now, Kuk plans to pursue a career in emergency medicine – not only because they are drawn to the excitement of the emergency room, but because the ER is a place where the most marginalized people tend to seek care.

"I have a special interest in the LGBTQ+ population, as I identify as queer and nonbinary," says Kuk. "A lot of people in this community and other marginalized communities access care through the ER and also tend to avoid medical care since there is a history of mistreatment and judgement from healthcare workers. How you carry yourself as a doctor, your compassion, that can make a huge difference in someone's care."

In addition to making a difference in the lives of LGBTQ+ patients, Kuk wants to make a difference in the lives of patients with cancer as well, like their mother had.

"We've diagnosed patients in the Emergency Department with cancer before," Kuk says. "I can't make cancer good news but how you deliver bad news and the compassion you show could make a world of difference to that patient and their family."

During their training, Kuk advocates for patients by delivering compassionate and inclusive care, whether they happen to have cancer or not. In addition to emphasizing their patient's pronouns and chosen names, they ask for inclusive social and sexual histories as well as using gender neutral language. In doing this, they hope to make medicine as a whole more accessible for people who have been historically pushed aside.

"I'm just one person, and I can't force everyone to respect you, if you're marginalized," Kuk says. "But I do want to push for a culture where people appreciate others who are different from them."